The trade war between the United States and China has lasted for more than one year — and a resolution is nowhere in sight.World Economyread more
The Fed is expected to cut rates Wednesday, but it is unlikely to tell markets what they want to hear on future rate cuts.Market Insiderread more
Pelosi said Trump should not have tried to address China's trade practices in a way that opened Americans up to financial pain.Politicsread more
Investors await the Fed's latest decision on monetary policy, set to be released on Wednesday stateside. The U.S. central bank is widely expected to cut rates by 25 basis...Asia Marketsread more
TransferWise posted an annual net profit of £10.3 million on revenues of £179 million.Technologyread more
Live the high life with a night's stay at Highclere Castle, the iconic stately home made famous by Downton Abbey.Spendread more
Large banking institutions face the risk of failure if interest rates in Europe continue to stay negative, warns the global chief economist of the Economist Intelligence Unit.Banksread more
The fallout from two fatal crashes of Boeing 737 Max planes has ensnared the manufacturer's most-loyal customer: Southwest Airlines. The carrier has canceled thousands of...Airlinesread more
Brent crude oil jumped the most in history in the previous session after attacks on Saudi's oil industry disrupted the kingdom's production.Marketsread more
In the survey, conducted after the third in the Democratic Party's series of debate, the former vice president draws 31% compared to 25% for the Massachusetts senator. At 14%,...2020 Electionsread more
Stocks rose slightly on Tuesday, but gains were capped as the Federal Reserve kicked off a two-day monetary policy meeting.US Marketsread more
Lawmakers are venting outrage over high prescription drug costs, but if Congress is looking for culprits, members might want to look in the mirror.
In the last 13 years, Congress passed major legislation that expanded taxpayer-financed coverage for prescription drugs but lacked explicit mechanisms for dealing with costs, instead relying mainly on market forces. Lawmakers look like unwitting enablers in the eyes of some experts.
"Congress, in attempting to expand access to prescription drugs, has inadvertently created a situation where price increases are much more rapid," said economist Paul Ginsburg, a former congressional adviser on Medicare who now directs the Brookings Institution health policy center.
Government-sponsored coverage injected more dollars into the market for medications, and new consumer protections curtailed some blunt instruments insurers used to control costs, such as annual and lifetime limits on the dollar value of coverage.
"The history we see over and over again is that when the government steps in as a guaranteed payer without regard to price, it will be taken advantage of," said Dr. Peter Bach, director of Memorial Sloan Kettering's Center for Health Policy and Outcomes.
More from NBC News:
Lawmakers accuse Mylan CEO of 'rope-a-doping' on EpiPen prices
Senate Republicans seek probe of Mylan's EpiPen oversight
Chuck Todd: Donald Trump needs to watch himself debate 'on mute'
Congressional indignation was on display recently as House members grilled Mylan CEO Heather Bresch about price increases for her company's EpiPens, prefilled syringes that deliver a rescue drug for people suffering life-threatening allergic reactions. The company was accused of gouging patients, but there was little introspection about the role of government.
It's not like a secret signal went out from Capitol Hill that it was OK for Mylan to charge $608 for an EpiPen two-pack. Instead, government policies foster an environment that makes it easier to introduce new medications at a high price and to charge more for existing drugs.
"It has dramatically changed the pricing environment," explained Ginsburg. "If a manufacturer sets the price higher, there will be less resistance to that price because a lot more people will be able to access that drug than in the past. The rational thing for the manufacturer would be to raise the prices both of existing drugs and newly introduced ones."
Consider the following:
"It's not clear to what extent Part D and the ACA may have directly caused the very large increases in drug prices in the last five years or so," said Rick Foster, formerly Medicare's chief actuary, or number-cruncher. "Having said that, it wouldn't surprise me if the significant increase in insurance coverage — and especially the catastrophic protection — contributed to the drug price increases."
The drug industry, a formidable lobby, rejects such speculation.
"Fundamentally, we disagree that there is not adequate cost containment for medicines built into Part D, or the ACA," said Lisa Joldersma, vice president of policy and research with the Pharmaceutical Research and Manufacturers of America.
"We think the market is best able to manage the holistic picture and to strike the right balance across cost containment, access and continuous innovation," she added.
The public seems receptive to government action. A Kaiser Family Foundation poll released Thursday shows strong support for requiring drug companies to disclose how they set prices (86 percent), Medicare negotiations (82 percent), price limits on costly drugs to treat cancer and diseases like hepatitis (78 percent), and allowing Americans to import medications from Canada (71 percent).
Rep. Xavier Becerra, a senior California Democrat, says he doesn't believe Obama's overhaul and Bush's prescription benefit are responsible for high-cost drugs. But he still thinks Congress has to act.
"I don't think there's anyone who doesn't believe we need to do more aggressive oversight of the industry," said Becerra.
It may be getting late, suggests Urban Institute economist Eugene Steuerle.
"Government simply cannot provide monopoly power and at the same time say that it will pay a price set in the private market by those companies," said Steuerle. "Turning the power of the purse over to monopolists is absurd."